Nephrotisches Syndrom-Studiennetzwerk (NEPTUNE)
Nephrotisches Syndrom-Studiennetzwerk im Rahmen des Klinischen Forschungsnetzwerks für seltene Krankheiten
Minimal change disease (MCD), focal segmental glomerulosclerosis (FSGS), and Membranous nephropathy (MN), generate an enormous individual and societal financial burden, accounting for approximately 12% of prevalent end stage renal disease (ESRD) cases (2005) at an annual cost in the US of more than $3 billion. However, the clinical classification of these diseases is widely believed to be inadequate by the scientific community. Given the poor understanding of MCD/FSGS and MN biology, it is not surprising that the available therapies are imperfect. The therapies lack a clear biological basis, and as many families have experienced, they are often not beneficial, and in fact may be significantly toxic. Given these observations, it is essential that research be conducted that address these serious obstacles to effectively caring for patients.
In response to a request for applications by the National Institutes of Health, Office of Rare Diseases (NIH, ORD) for the creation of Rare Disease Clinical Research Consortia, a number of affiliated universities joined together with The NephCure Foundation the NIDDK, the ORDR, and the University of Michigan in collaboration towards the establishment of a Nephrotic Syndrome (NS) Rare Diseases Clinical Research Consortium.
Through this consortium the investigators hope to understand the fundamental biology of these rare diseases and aim to bank long-term observational data and corresponding biological specimens for researchers to access and further enrich.
Studienübersicht
Status
Status
Bedingungen
Bedingungen
Intervention / Behandlung
Intervention / Behandlung
Detaillierte Beschreibung
Idiopathic Nephrotic Syndrome (NS) is a rare disease syndrome responsible for approximately 12% of all causes of end-stage kidney disease (ESRD) and up to 20% of ESRD in children. Treatment strategies for Focal and Segmental Glomerulosclerosis (FSGS), Minimal Change Disease (MCD) and Membranous Nephropathy (MN), the major causes of NS, include high dose prolonged steroid therapy, cyclophosphamide, cyclosporine A, tacrolimus, mycophenolate mofetil and other immunosuppressive agents, which all carry significant side effects. Failure to obtain remission using the current treatment approaches frequently results in progression to ESRD with its associated costs, morbidities, and mortality. In the North American Pediatric Renal Trials and Collaborative Studies (NAPRTCS) registry, half of the pediatric patients with Steroid Resistant Nephrotic Syndrome required renal replacement therapy within two years of being enrolled in the disease registry. FSGS also has a high recurrence rate following kidney transplantation (30-40%) and is the most common recurrent disease leading to allograft loss.
The prevailing classification of Nephrotic Syndrome categorizes patients into FSGS, MCD, and MN, if in the absence of other underlying causes, glomerular histology shows a specific histological pattern. This classification does not adequately predict the heterogeneous natural history of patients with FSGS, MCD, and MN. Major advances in understanding the pathogenesis of FSGS and MCD have come over the last ten years from the identification of several mutated genes responsible for causing Steroid Resistant Nephrotic Syndrome (SRNS) presenting with FSGS or MCD histopathology in humans and model organisms. These functionally distinct genetic disorders can present with indistinguishable FSGS lesions on histology confirming the presence of heterogeneous pathogenic mechanisms under the current histological diagnoses.
The limited understanding of FSGS, MCD, and MN biology in humans has necessitated a descriptive classification system in which heterogeneous disorders are grouped together. This invariably consigns these heterogeneous patients to the same therapeutic approaches, which use blunt immunosuppressive drugs that lack a clear biological basis, are often not beneficial, and are complicated by significant toxicity. The foregoing shortcomings make a strong case that concerted and innovative investigational strategies combining basic science, translational, and clinical methods should be employed to study FSGS, MCD, and MN. It is for these reasons that the Nephrotic Syndrome Study Network is established to conduct clinical and translational research in patients with FSGS/MCD and MN.
Studientyp
Studientyp
Einschreibung (Geschätzt)
Einschreibung
Kontakte und Standorte
Studienkontakt
Studienkontakt
- Name: Chrysta C. Lienczewski, BS
- Telefonnummer: 734-615-5021
- E-Mail: NEPTUNE-Study@umich.edu
Studieren Sie die Kontaktsicherung
- Name: Amanda Williams, BS
- Telefonnummer: 734-615-5017
- E-Mail: NEPTUNE-Study@umich.edu
Studienorte
-
-
Ontario
-
Richmond Hill, Ontario, Kanada, L4C 4Z3
- Abgeschlossen
- York Central Hospital
-
Scarborough Village, Ontario, Kanada, M1H 3G4
- Abgeschlossen
- Scarborough Hospital
-
Toronto, Ontario, Kanada, M4N 3M5
- Rekrutierung
- Sunnybrook Hospital
-
Hauptermittler:
- Michelle Hladunewich, MD
-
Kontakt:
- Rhea O'Neill
- E-Mail: rhea.oneill@sri.utoronto.ca
-
Toronto, Ontario, Kanada, L5M 2N1
- Rekrutierung
- Credit Valley Hospital
-
Unterermittler:
- Phillip Boll, MD
-
Kontakt:
- Martin Romano, MD
- Telefonnummer: 416-340-3514
- E-Mail: martin.romano@thp.ca
-
Toronto, Ontario, Kanada, M5G2C4
- Rekrutierung
- University Health Network
-
Kontakt:
- Paul Ling, MD
- Telefonnummer: 416-340-3514
- E-Mail: pling@uhnresearch.ca
-
Kontakt:
- Martin Romano, MD
- E-Mail: Martin.Romano@trilliumhealthpartners.ca
-
Hauptermittler:
- Daniel Cattran, MD
-
Unterermittler:
- Heather Reich, MD
-
Unterermittler:
- Michelle Hladunewich, MD
-
-
-
-
California
-
Los Angeles, California, Vereinigte Staaten, 90227
- Rekrutierung
- University of Southern California-Children's Hospital
-
Hauptermittler:
- Kevin Lemley, MD, PhD
-
Kontakt:
- Sharon Tang, BSN
- Telefonnummer: 323-361-7299
- E-Mail: shatang@chla.usc.edu
-
Palo Alto, California, Vereinigte Staaten, 94304
- Rekrutierung
- Stanford University School of Medicine
-
Kontakt:
- Kshama Mehta, PhD
- Telefonnummer: 650-736-1822
- E-Mail: krmehta@stanford.edu
-
Hauptermittler:
- Richard Lafayette, MD
-
San Francisco, California, Vereinigte Staaten, 94158
- Noch keine Rekrutierung
- University of California San Francisco Benioff Children's Hospitals
-
Hauptermittler:
- Paul Brakeman, MD, PhD
-
Kontakt:
- Daniel Schrader
- E-Mail: daniel.schrader@ucsf.edu
-
Torrance, California, Vereinigte Staaten, 90502
- Rekrutierung
- Lundquist Biomedical Research Institute at Harbor UCLA Medical Center
-
Kontakt:
- Janine LaPage
- Telefonnummer: 310-222-4104
- E-Mail: jlapage@labiomed.org
-
Hauptermittler:
- Sharon Adler, MD
-
-
Colorado
-
Aurora, Colorado, Vereinigte Staaten, 80045
- Noch keine Rekrutierung
- Children's Hospital Colorado
-
Kontakt:
- Nathan Rogers
- E-Mail: Nathan.Rogers@childrenscolorado.org
-
Unterermittler:
- Gabriel Cara-Fuentes, MD
-
Aurora, Colorado, Vereinigte Staaten, 80045
- Noch keine Rekrutierung
- University of Colorado Anschutz School of Medicine
-
Hauptermittler:
- Amber Podoll, MD
-
Kontakt:
- Elizabeth Wagner
- E-Mail: elizabeth.c.wagner@cuanschutz.edu
-
-
Florida
-
Miami, Florida, Vereinigte Staaten, 33136
- Rekrutierung
- University of Miami Miller School of Medicine
-
Kontakt:
- Carlos Bidot
- Telefonnummer: 305-243-8973
- E-Mail: cbidot2@miami.edu
-
Hauptermittler:
- Alessia Fornoni, MD. PhD
-
-
Georgia
-
Atlanta, Georgia, Vereinigte Staaten, 30322
- Rekrutierung
- Emory University and Children's Healthcare of Atlanta
-
Hauptermittler:
- Laurence Greenbaum, MD, PhD
-
Kontakt:
- Emily Yun
- Telefonnummer: 404-712-9998
- E-Mail: emily.yun@emory.edu
-
-
Illinois
-
Chicago, Illinois, Vereinigte Staaten, 60680
- Rekrutierung
- John Stroger Cook County Hospital
-
Kontakt:
- Mathew Itteera
- Telefonnummer: 312-864-4614
- E-Mail: mitteera@cookcountyhhs.org
-
Hauptermittler:
- Ambarish Athavale, MD
-
-
Kansas
-
Kansas City, Kansas, Vereinigte Staaten, 66160
- Rekrutierung
- University of Kansas Medical Center
-
Kontakt:
- Catherine Creed
- E-Mail: ccreed@kumc.edu
-
Hauptermittler:
- Ellen McCarthy, MD
-
-
Maryland
-
Baltimore, Maryland, Vereinigte Staaten, 21287
- Rekrutierung
- Johns Hopkins Medical Institute
-
Kontakt:
- Sara Boynton
- Telefonnummer: 443-287-9051
- E-Mail: sboynto3@jhmi.edu
-
Hauptermittler:
- Alicia Neu, MD
-
Unterermittler:
- Michael Choi, MD
-
Bethesda, Maryland, Vereinigte Staaten, 20892
- Abgeschlossen
- Kidney Disease Section, NIDDK, NIH
-
-
Michigan
-
Ann Arbor, Michigan, Vereinigte Staaten, 48109
- Rekrutierung
- University of Michigan Medical Center
-
Kontakt:
- Chrysta C. Lienczewski, BS - adult
- Telefonnummer: 734-615-5021
- E-Mail: boridley@med.umich.edu
-
Hauptermittler:
- Matthias Kretzler, MD
-
Kontakt:
- Amanda Williams, BS - adult
- Telefonnummer: 734-615-5017
- E-Mail: amwi@umich.edu
-
Ann Arbor, Michigan, Vereinigte Staaten, 48109
- Rekrutierung
- CS Mott Children's Hospital, University of Michigan
-
Unterermittler:
- Debbie Gipson, MD, MS
-
Kontakt:
- Hailey Desmond, MS
- Telefonnummer: 734-232-4851
- E-Mail: heturner@umich.edu
-
-
Minnesota
-
Rochester, Minnesota, Vereinigte Staaten, 55905
- Abgeschlossen
- Mayo Clinic
-
-
Missouri
-
Kansas City, Missouri, Vereinigte Staaten, 64108
- Rekrutierung
- Children's Mercy Hospital
-
Hauptermittler:
- Tarak Srivastava, MD
-
Kontakt:
- Kelsey Markus
- E-Mail: kemarkus@cmh.edu
-
St Louis, Missouri, Vereinigte Staaten, 63110
- Noch keine Rekrutierung
- Washington University - St Louis
-
Kontakt:
- Leslie Walther
- E-Mail: leslie.walther@wustl.edu
-
Hauptermittler:
- Vikas Dharnidharka, MD, PhD
-
-
New York
-
New Hyde Park, New York, Vereinigte Staaten, 11040
- Rekrutierung
- Cohen Children's Hospital
-
Hauptermittler:
- Christine Sethna, MD
-
Kontakt:
- Suzanne Vento, BSN
- Telefonnummer: 718-470-3499
- E-Mail: svento@northwell.edu
-
New York, New York, Vereinigte Staaten, 10032
- Rekrutierung
- Columbia University Medical Center
-
Hauptermittler:
- Andrew Bomback, MD, MPH
-
Kontakt:
- Anup Pradhan
- Telefonnummer: 212-305-6842
- E-Mail: arp2209@cumc.columbia.edu
-
New York, New York, Vereinigte Staaten, 10010
- Rekrutierung
- New York University Medical Center
-
Kontakt:
- Frank Modersitzki, MPH - adult
- Telefonnummer: 6379 212-686-7500
- E-Mail: Frank.Modersitzki@va.gov
-
Hauptermittler:
- Olga Zhadnova, MD
-
Hauptermittler:
- Howard Trachtman, MD
-
Kontakt:
- Laura Jane Pehrson - peds
- E-Mail: laurajane.pehrson@nyulangone.org
-
New York, New York, Vereinigte Staaten, 10016
- Rekrutierung
- Bellevue Hospital
-
Kontakt:
- Frank Modersitzki, MPH
- Telefonnummer: 6379 212-686-7500
- E-Mail: Frank.Modersitzki@va.gov
-
Hauptermittler:
- Laura Barisoni, MD
-
Unterermittler:
- Olga Zhadnova, MD
-
New York, New York, Vereinigte Staaten, 10016
- Rekrutierung
- New York University Veterans Administration
-
Kontakt:
- Frank Modersitzki, MPH
- Telefonnummer: 6379 212-686-7500
- E-Mail: Frank.Modersitzki@va.gov
-
Hauptermittler:
- Laura Barisoni, MD
-
Unterermittler:
- Olga Zhadnova, MD
-
The Bronx, New York, Vereinigte Staaten, 11040
- Rekrutierung
- Montefiore Medical Center
-
Kontakt:
- Patti Flynn, RN
- Telefonnummer: 718-655-1120
- E-Mail: pflynn@montefiore.org
-
Unterermittler:
- Robert Woroniecki, MD
-
Hauptermittler:
- Frederick Kaskel, MD
-
-
North Carolina
-
Chapel Hill, North Carolina, Vereinigte Staaten, 27599
- Rekrutierung
- University of North Carolina at Chapel Hill
-
Kontakt:
- Anne Froment
- Telefonnummer: 919-923-1382
- E-Mail: Anne_Froment@med.unc.edu
-
Hauptermittler:
- Patrick H. Nachman, MD
-
Unterermittler:
- Susan L. Hogan, PhD, MPH
-
Unterermittler:
- Keisha Gibson, MD
-
Kontakt:
- Fernanda Ochoa
- E-Mail: ferochoa@email.unc.edu
-
Charlotte, North Carolina, Vereinigte Staaten, 28203
- Rekrutierung
- Atrium Health Levine Children's Hospital
-
Hauptermittler:
- Susan Massengill, MD
-
Kontakt:
- Layla Lo
- E-Mail: nkauj.lo@atriumhealth.org
-
Winston-Salem, North Carolina, Vereinigte Staaten, 27157
- Zurückgezogen
- Wake Forest School of Medicine
-
-
Ohio
-
Cleveland, Ohio, Vereinigte Staaten, 44195
- Rekrutierung
- Cleveland Clinic
-
Unterermittler:
- Katherine Dell, MD
-
Kontakt:
- Stefanie Larson
- E-Mail: larsons2@ccf.org
-
Kontakt:
- Villarreal
-
Cleveland, Ohio, Vereinigte Staaten, 44106
- Abgeschlossen
- University Hospital Rainbow Babies & Children's Hospital
-
Cleveland, Ohio, Vereinigte Staaten, 44109
- Abgeschlossen
- MetroHealth Hospital at Case Western Medical Center
-
Columbus, Ohio, Vereinigte Staaten, 43210
- Rekrutierung
- The Ohio State University Wexner Medical Center
-
Kontakt:
- Alexander Price
- E-Mail: alexander.price2@osumc.edu
-
Hauptermittler:
- Salem Almaani, MD
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Vereinigte Staaten, 19104
- Rekrutierung
- University of Pennsylvania
-
Kontakt:
- Krishna Kallem, MD - adult, MS
- Telefonnummer: 484-358-0315
- E-Mail: krishna.kallem@uphs.upenn.edu
-
Hauptermittler:
- Lawrence Holzman, MD
-
Kontakt:
- Aliya Edwards - peds
- E-Mail: EdwardsA1@chop.edu
-
Philadelphia, Pennsylvania, Vereinigte Staaten, 19104
- Rekrutierung
- Children's Hospital of Philadelphia
-
Unterermittler:
- Kevin Meyers, MD
-
Kontakt:
- Alilya Edwards
- E-Mail: EdwardsA1@chop.edu
-
Philadelphia, Pennsylvania, Vereinigte Staaten, 19140
- Rekrutierung
- Temple University
-
Kontakt:
- Zoe Pfeffer, BS
- Telefonnummer: 215-707-4712
- E-Mail: zoe.pfeffer@tuhs.temple.edu
-
Hauptermittler:
- Crystal Gadegbeku, MD
-
Hauptermittler:
- Iris Lee, MD
-
-
South Carolina
-
Charleston, South Carolina, Vereinigte Staaten, 29425
- Rekrutierung
- Medical University of South Carolina
-
Hauptermittler:
- David Selewski, MD, MS
-
-
Texas
-
Dallas, Texas, Vereinigte Staaten, 75390
- Rekrutierung
- University of Texas-Southwestern
-
Hauptermittler:
- Kamal Sambandam, MD
-
Kontakt:
- Elizabeth Robles
- E-Mail: elizabeth.robles@utsouthwestern.edu
-
Houston, Texas, Vereinigte Staaten, 77030
- Rekrutierung
- Texas Children's Hospital - Baylor College of Medicine
-
Kontakt:
- Aisha Deslandes
- E-Mail: aisha.deslandes@bcm.edu
-
Hauptermittler:
- Shweta S. Shah, MD
-
-
Washington
-
Seattle, Washington, Vereinigte Staaten, 98195
- Rekrutierung
- University of Washington
-
Hauptermittler:
- Peter J. Nelson, MD
-
Kontakt:
- Linda Manahan, BSN
- E-Mail: lmanahan@nephrology.washington.edu
-
Seattle, Washington, Vereinigte Staaten, 98145
- Rekrutierung
- Seattle Children's Hospital
-
Unterermittler:
- Sangeeta Hingorani, MD
-
Kontakt:
- Emily Pao
- E-Mail: emily.pao@seattlechildrens.org
-
Spokane, Washington, Vereinigte Staaten, 99204
- Rekrutierung
- Providence Medical Research Center
-
Kontakt:
- Ann Cooper, CCRC
- Telefonnummer: 509-474-4327
- E-Mail: Ann.Cooper@providence.org
-
Unterermittler:
- Katherine Tuttle, MD
-
Kontakt:
- Kelli Kuykendall, CCRC
- Telefonnummer: 509-474-4320
- E-Mail: Kelli.Kuykendall@providence.org
-
-
Teilnahmekriterien
Zulassungskriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Probenahmeverfahren
Studienpopulation
Patients with signs and symptoms of kidney disease consistent with FSGS, MCD, MN or proteinuric renal disease or pediatric participants not previously biopsied, who present for patient care at participating clinical centers will be eligible for Cohort A (biopsy cohort) study population targeted for enrollment into the NEPTUNE study.
To establish a cohort of pediatric participants with incident nephrotic syndrome, Cohort B, a non-biopsy cohort has been initiated for Protocol V4.0. This population, <19 years of age, presenting for nephrotic syndrome and less than 30 days of immunosuppression therapy exposure, will also be targeted for enrollment into the cNEPTUNE study.
Potential participants willing to receive their initial care and subsequent follow-up study visits at one of these sites are welcome to participate.
Beschreibung
Cohort A (biopsy cohort) Inclusion Criteria:
Patients presenting with an incipient clinical diagnosis for FSGS/MCD or MN or pediatric participants not previously biopsied, with a clinical diagnosis for FSGS/MCD or MN meeting the following inclusion criteria:
- Documented urinary protein excretion ≥1500 mg/24 hours or spot protein: creatinine ratio equivalent at the time of diagnosis or within 3 months of the screening/eligibility visit.
- Scheduled renal biopsy
Cohort B (non-biopsy, cNEPTUNE) Inclusion Criteria:
-
Age <19 years of age
-
Initial presentation with <30 days immunosuppression therapy
-
Proteinuria/nephrotic
- UA>2+ and edema OR
- UA>2+ and serum albumin <3 OR
- UPC > 2g/g and serum albumin <3
Exclusion Criteria (Cohort A&B):
- Prior solid organ transplant
- A clinical diagnosis of glomerulopathy without diagnostic renal biopsy
- Clinical, serological or histological evidence of systemic lupus erythematosus (SLE) as defined by the ARA criteria. Patients with membranous in combination with SLE will be excluded because this entity is well defined within the International Society of Nephrology/Renal Pathology Society categories of lupus nephritis, and frequently overlaps with other classification categories of SLE nephritis (68)
- Clinical or histological evidence of other renal diseases (Alport, Nail Patella, Diabetic Nephropathy, IgA-nephritis, monoclonal gammopathy (multiple myelomas), genito-urinary malformations with vesico-urethral reflux or renal dysplasia)
- Known systemic disease diagnosis at time of enrollment with a life expectancy less than 6 months
- Unwillingness or inability to give a comprehensive informed consent
- Unwillingness to comply with study procedures and visit schedule
- Institutionalized individuals (e.g., prisoners)
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Beobachtungsmodelle: COHORT
- Zeitperspektiven: PROSPECTIVE
Anzahl der Gruppen / Kohorten
Kohorten und Interventionen
Gruppe / KohorteGruppe / Kohorte |
Intervention / BehandlungIntervention / Behandlung |
|---|---|
|
FSGS/MCD Cohort (Cohort A)
Focal Segmental Glomerulosclerosis/Minimal Change Disease (FSGS/MCD) Cohort Participants enrolled in NEPTUNE with a biopsy proven histological diagnosis for FSGS or MCD. Eligible participants must be scheduled for a clinically indicated renal biopsy. |
Patients scheduled to undergo a clinically indicated kidney biopsy will be requested to consent to an additional renal core, to be set aside until all clinical care is complete. |
|
MN Cohort (Cohort A)
Membranous Nephropathy (MN) Cohort Participants enrolled in NEPTUNE with a biopsy proven histological diagnosis for MN. Eligible participants must be scheduled for a clinically indicated renal biopsy. |
Patients scheduled to undergo a clinically indicated kidney biopsy will be requested to consent to an additional renal core, to be set aside until all clinical care is complete. |
|
Other glomerulopathies cohort
Participants enrolled in NEPTUNE and determined to not have FSGS/MCD or MN will be followed in a third group. Eligible participants must be scheduled for a clinically indicated renal biopsy. |
Patients scheduled to undergo a clinically indicated kidney biopsy will be requested to consent to an additional renal core, to be set aside until all clinical care is complete. |
|
cNEPTUNE (Cohort B)
Participants < 19 years of age, with < 30 days exposure to immunosuppression therapy who are not scheduled for renal biopsy. |
Was misst die Studie?
Primäre Ergebnismessungen
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Event rate of change in urinary protein excretion and renal function.
Zeitfenster: 60 months
|
Defined as remission, partial remission and non-remission |
60 months
|
|
Rate of change in renal function.
Zeitfenster: 60 months
|
Defined as:
|
60 months
|
Sekundäre Ergebnismessungen
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Quality of Life:
Zeitfenster: 60 months
|
Patient-reported outcome will be assessed using Quality of Life questionnaires at regular intervals as stipulated in the visit calendar using the SF-36, PedsQL and the Patient Reported Outcome Measurement Information System (PROMIS) (in the age-appropriate groups). |
60 months
|
|
Malignancies
Zeitfenster: 60 months
|
Any cancer diagnosis of the skin, hematopoietic system, or solid organ after enrollment in NEPTUNE |
60 months
|
|
Infections, Serious and Systemic
Zeitfenster: 60 months
|
Infections including one of the following:
|
60 months
|
|
Thromboembolic Events
Zeitfenster: 60 months
|
Documented diagnosis of one of the following:
|
60 months
|
|
Hospitalization
Zeitfenster: 60 months
|
Documented hospital admission, including observation for ≥24 hours. |
60 months
|
|
Emergency Department/ Observation Unit Visit
Zeitfenster: 60 months
|
Documented visit to an emergency department or observation unit that does not lead to hospitalization and is less than 24 hours. |
60 months
|
|
Acute Kidney Injury
Zeitfenster: 60 months
|
Documented diagnosis of acute kidney injury as defined by the AKIN (Mehta et al., Critical Care 2007, 11:R31) and/or renal failure requiring renal replacement therapy <3 months. |
60 months
|
|
Death
Zeitfenster: 60 months
|
|
60 months
|
|
New Onset Diabetes
Zeitfenster: 60 months
|
Diagnosis of diabetes as indicated by 1 or more of the following not present at NEPTUNE Enrollment:
|
60 months
|
Mitarbeiter und Ermittler
Sponsor
Sponsor
Mitarbeiter
Mitarbeiter
Ermittler
Ermittler
- Hauptermittler: Matthias Kretzler, MD, University of Michigan
Publikationen und hilfreiche Links
Allgemeine Veröffentlichungen
- Wang CS, Troost JP, Wang Y, Greenbaum LA, Gibson K, Trachtman H, Srivastava T, Reidy K, Kaskel F, Sethna CB, Meyers K, Dell KM, Tran CL, Hingorani S, Lemley KV, Lin JJ, Gipson DS. Determinants of medication adherence in childhood nephrotic syndrome and associations of adherence with clinical outcomes. Pediatr Nephrol. 2022 Jul;37(7):1585-1595. doi: 10.1007/s00467-021-05176-8. Epub 2021 Nov 18.
- Solagna F, Tezze C, Lindenmeyer MT, Lu S, Wu G, Liu S, Zhao Y, Mitchell R, Meyer C, Omairi S, Kilic T, Paolini A, Ritvos O, Pasternack A, Matsakas A, Kylies D, Wiesch JSZ, Turner JE, Wanner N, Nair V, Eichinger F, Menon R, Martin IV, Klinkhammer BM, Hoxha E, Cohen CD, Tharaux PL, Boor P, Ostendorf T, Kretzler M, Sandri M, Kretz O, Puelles VG, Patel K, Huber TB. Pro-cachectic factors link experimental and human chronic kidney disease to skeletal muscle wasting programs. J Clin Invest. 2021 Jun 1;131(11):e135821. doi: 10.1172/JCI135821.
- Kang H, Kim DR, Jung YH, Baek CW, Park YH, In Oh J, Kim WJ, Choi GJ. Pre-warming the Streamlined Liner of the Pharynx Airway (SLIPA) improves fitting to the laryngeal structure: a randomized, double-blind study. BMC Anesthesiol. 2015 Nov 20;15:167. doi: 10.1186/s12871-015-0151-4.
- Hogan MC, Lieske JC, Lienczewski CC, Nesbitt LL, Wickman LT, Heyer CM, Harris PC, Ward CJ, Sundsbak JL, Manganelli L, Ju W, Kopp JB, Nelson PJ, Adler SG, Reich HN, Holzmann LB, Kretzler M, Bitzer M. Strategy and rationale for urine collection protocols employed in the NEPTUNE study. BMC Nephrol. 2015 Nov 17;16:190. doi: 10.1186/s12882-015-0185-3.
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Studienbeginn
Primärer Abschluss (Geschätzt)
Primärer Abschluss
Studienabschluss (Geschätzt)
Studienabschluss
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Geschätzt)
Zuerst gepostet
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes Update gepostet
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
- Urogenitale Erkrankungen
- Männliche Urogenitalerkrankungen
- Nierenerkrankungen
- Urologische Erkrankungen
- Weibliche Urogenitalerkrankungen
- Weibliche Urogenitalerkrankungen und Schwangerschaftskomplikationen
- Autoimmunerkrankungen
- Erkrankungen des Immunsystems
- Glomerulonephritis
- Nephritis
- Nephrose
- Nephrotisches Syndrom
- Glomerulonephritis, membranös
- Glomerulosklerose, fokal segmental
- Nephrose, Lipoid
- Makula Dystrophie, Hornhauttyp 1
Andere Studien-ID-Nummern
Andere Studien-ID-Nummern
- 6801
- 1U54DK083912 (US NIH Stipendium/Vertrag)
- 1R01DK141114-01A1 (US NIH Stipendium/Vertrag)
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .